Clinical trial
Faslodex in McCune-Albright Syndrome
NCT00278915 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00278915 |
|---|---|
| Title | Faslodex in McCune-Albright Syndrome |
| Official title | An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome |
| Acronym | FMAS |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Puberty, Precocious, McCune-Albright Syndrome |
| Intervention type | Drug |
| Interventions | Fulvestrant |
| Enrollment | 30 |
| Start date | Jan 31, 2006 |
| Primary completion | Dec 8, 2009 |
| Completion | Jul 20, 2023 |
| First posted | Jan 19, 2006 |
| Last update posted | Mar 5, 2024 |
| Countries | France, Germany, Italy, Russia, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: